FIELD: chemistry.
SUBSTANCE: invention relates to a co-crystalline form of 1-[5-(4-chlorophenylamino)-1,2,4-thiadiazol-3-yl]-propan-2-ol with oxalic acid, where the molar ratio of 1-[5-(4-chlorophenylamino)-1,2,4-thiadiazol-3-yl]-propan-2-ol with oxalic acid is 2:1, having an endothermic peak of 150 to 170 °C according to measurement data using differential scanning calorimetry, having peaks at angle 2θ(°) 6.5, 13.2, 14.3, 14.9, 16.5, 16.7, 18.7, 19.4, 19.7, 20.0, 20.7, 22.1, 23.3, 23.7, 24.8 according to X-ray powder diffraction measurement data having characteristic vibration frequencies 3442, 2973, 1643, 1493 , 1335, 1268, 1128, 1096, 1066, 941, 820, 744 cm-1 according to infrared spectroscopy.
EFFECT: co-crystalline form of 1-[5-(4-chlorophenylamino)-1,2,4-thiadiazol-3-yl]-propan-2-ol with oxalic acid is suitable for use in pharmaceutical industry as a component of a pharmaceutical preparation for treating various neurodegenerative diseases, including in therapy of Alzheimer's disease, with simultaneous increase of solubility.
1 cl, 8 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CO-CRYSTALLINE FORM OF 1-[(5-PARA-METHYL-META-CHLORO-PHENYLAMINO)-1,2,4-THIADIAZOL-3-YL]-PROPAN-2-OL | 2019 |
|
RU2721335C1 |
| DIFLUNISAL CO-CRYSTALLINE FORM | 2016 |
|
RU2617849C1 |
| CRYSTALLINE FORMS GLYT1 | 2007 |
|
RU2463295C2 |
| COCRYSTALLINE FORM OF 2,8-DIMETHYL-5-PHENETHYL-2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-b]INDOLE | 2022 |
|
RU2806046C1 |
| HYDRATE OF CIPROFLOXACIN SALT WITH 4-AMINOBENZOIC ACID | 2019 |
|
RU2706351C1 |
| COCRYSTALLINE FORM OF NIFLUMIC ACID WITH ISONICOTINAMIDE OT CAFFEINE | 2013 |
|
RU2536484C1 |
| CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE WITH SALICYLIC ACID | 2013 |
|
RU2539350C1 |
| CO-CRYSTALLINE FORM OF 2-HYDROXYBENZAMIDE AND 4-AMINOBENZOIC ACID | 2012 |
|
RU2497804C1 |
| MULTICOMPONENT CRYSTALS COMPRISING DASATINIB AND SELECTED COCRYSTAL FORMERS | 2013 |
|
RU2650524C2 |
| CO-CRYSTALLINE FORM OF THEOPHYLLINE WITH DIFLUNISAL OR DICLOFENAC | 2013 |
|
RU2542100C1 |
